Generic Entry Reforms Gain Steam In Congress With House Committee Passage
Bills to reign in petitions, pay-for-delay, product hopping, and patent thickets clear House Judiciary Committee. Legislation may have better shot at enactment this time around given bipartisan support in both House and Senate Committees.
You may also be interested in...
The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.
Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.
The US off-patent industry has welcomed the news that Robert Califf looks likely to serve a second term as US Food and Drug Administration commissioner, after his nomination by US President Joe Biden.